Bioteque (ROCO:4107) LT-Debt-to-Total-Asset: 0.09 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4107 Bioteque Corp ROCO:4107
85 GF Score
Price NT$118.50
GF Value NT$129.51
Valuation Fairly Valued
View Full Analysis

What is Bioteque LT-Debt-to-Total-Asset?

Bioteque ROCO:4107 +1.28% 85 LT-Debt-to-Total-Asset is 0.09 as of Dec. 2025. GuruFocus rates ROCO:4107 with a GF Score™ of 85/100 and a GF Value™ of NT$129.51 (Fairly Valued).

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bioteque's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.09.

Bioteque's long-term debt to total assets ratio declined from Dec. 2024 (0.13) to Dec. 2025 (0.09). It may suggest that Bioteque is progressively becoming less dependent on debt to grow their business.

Bioteque  (ROCO:4107) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bioteque LT-Debt-to-Total-Asset Related Terms

Bioteque LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Bioteque's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioteque LT-Debt-to-Total-Asset Chart

Bioteque Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.18 0.16 0.13 0.09

Bioteque Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.11 0.11 0.11 0.09
ROCO:4107
85GF Score
Bioteque Corp ROCO:4107
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioteque LT-Debt-to-Total-Asset Calculation

Bioteque's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=439.394/4659.999
=0.09

Bioteque's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=439.394/4659.999
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.09 mean?
Bioteque (ROCO:4107) has a LT-Debt-to-Total-Asset of 0.09 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bioteque and its competitors.
Is Bioteque's LT-Debt-to-Total-Asset too high?
Bioteque's current LT-Debt-to-Total-Asset is 0.09. Overall, Bioteque has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bioteque's LT-Debt-to-Total-Asset compare to ISRG and BDX?
Bioteque's LT-Debt-to-Total-Asset of 0.09 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bioteque and its competitors. Bioteque's current LT-Debt-to-Total-Asset is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioteque stock overvalued right now?
Based on GuruFocus' analysis, Bioteque (ROCO:4107) is currently considered Fairly Valued. The stock's GF Value™ is NT$129.51, compared to a current price of NT$118.50 — trading 8.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.09. Bioteque's overall GF Score™ is 85/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Bioteque (ROCO:4107), the current LT-Debt-to-Total-Asset is 0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioteque (ROCO:4107) Overvalued in 2026?

Based on GuruFocus' analysis, Bioteque stock appears to be undervalued. The current stock price of NT$118.50 is trading 8.5% below its estimated GF Value™ of NT$129.51. GuruFocus considers Bioteque to be Fairly Valued.

Key valuation signals for ROCO:4107:

  • LT-Debt-to-Total-Asset: 0.09
  • GF Value™: NT$129.51 vs. price of NT$118.50 (8.5% below fair value)
  • GF Score™: 85/100

No single metric tells the full story. See the ROCO:4107 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioteque Business Description

Address Chang-An E. Road, 5th Floor-6, No.23, Section 1, Taipei, TWN, 104
Bioteque Corp is engaged in manufacturing, trading, and selling medical equipment and instruments. The company operates in different segments such as Manufacturing medical disposables for hemodialysis use, and selling them to dealers and retailers; Manufacturing and selling catheters for healthcare and medical PVC IV bags to medical organizations; Manufacturing and selling medical key components and inner catheters to the medical organization; and Other segment. Geographically, the company generates a majority of its revenue from Asia and the rest from North America, South America, and other regions.
85GF Score

Get the complete analysis for ROCO:4107

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$118.50
Price
NT$129.51
GF Value